Objective A strong positive correlation between estimated glomerular filtration rate (eGFR) multiplied by follow-up time and memory function has been demonstrated previously. The purpose of this study was to investigate the factors affecting progression of cognitive dysfunction in the elderly with different levels of kidney function. Methods In April 2002, a prospective study on progression of cognitive function was conducted on 356 elderly people. All participants received a comprehensive geriatric assessment, serum biochemical test, homeostasis model assessment (HOMA), and a genetic polymorphism study, including polymorphism of apolipoprotein E (APOE), Cystatin, C-reactive protein (CRP) and tumor necrosis factor (TNF). Lean body massadjusted eGFR was used to evaluate severity of chronic kidney disease (CKD), and a clinical dementia rating scale was used to assess cognitive dysfunction. Patients were stratified according to eGFR ( 49 mL/min and <49 mL/min). Results Using multivariate logistic regression models, older age (OR=1.27, 95% CI=1.00-1.61) was associated with a high risk for progression of cognitive function in patients with a relatively low eGFR. In patients with lower eGFR, higher mini-mental state examination (MMSE) scores (OR=0.23, 95% CI=0.10-0.54) were correlated with a low risk for progression of cognition, while in patients with higher eGFR, higher MMSE scores (OR=0.39, 95% CI=0.23-0.65) were less correlated with cognitive dysfunction. However, elevated serum plasminogen activator inhibitor-1 (PA1-1) was associated with a high risk for cognitive dysfunction (OR=1.06, 95% CI=1.01-1.11) in patients with a better eGFR. Conclusion Age, MMSE score and serum PAI-1 were found to be factors that predicted cognitive dysfunction at different functional levels of CKD.
Introduction
Cognitive dysfunction increases in prevalence with CKD severity, potentially affecting up to 80% of patients, especially in populations of older persons (1) . A 0.5-unit decrease in 1/SCr (eg. SCr from 1.0 to 2.0) has been demonstrated to be associated with a 26% increased risk of inci- Frailty n=15 dent dementia (2) . In addition, a strong positive correlation has been shown between eGFR multiplied by follow-up period and memory function (3) . Furthermore, there were no significant differences between the survival curves of elderly dementia and patients with cancer who were receiving treatment as well as those who did not receive treatment (4) .
More than one-third of patients aged 70 years and older have moderate CKD (eGFR 30-59 mL/min/1.73 m 2 ) (5) . Serum creatinine is an unreliable indicator of glomerular filtration rate in individuals with increased age, particularly in those who are sick or malnourished, or both, due to agerelated diminution of muscle mass (6) . The Jelliffe-1973 equation, Cockcroft-Gault equation, and Hull equation were considered to be more accurate in elderly Chinese CKD patients (7) . It has been well established that people who are prone to progression of dementia have multiple co-morbidity and mild cognitive impairment at baseline. Few studies have investigated the factors affecting progression of cognitive dysfunction in different groups of elderly CKD patients. Therefore, the purpose of this study was to determine the factors affecting cognitive decline in elderly patients with chronic CKD in a long-term care facility in central Taiwan.
Materials and Methods

Sample
In April 2002, a prospective study on the evolution of cognitive function in a group of elderly CKD people was carried out in a long-term care facility in central Taiwan (Changhua Domiciliary Center, Veteran Affairs Commission, Executive Yuan, R.O.C.). This project was approved by the institution review board of our hospital (code No. 940119/ 500) and an informed consent form was signed by each par-ticipant. A total of 356 cases were enrolled at the study at the beginning. Forty-two patients withdrew from the study, 30 were transferred to another facility, 97 cases died, and 72 cases were lost to follow-up for unknown reasons. Therefore, only 125 cases were followed up until the end of the study, and these 125 cases were further stratified according to cognitive function and renal function ( Fig. 1 ).
Assessment
The following parameters were assessed in all of the participants: lean body mass using a bioelectrical impedance method (Model BIA-101, RJL Systems, Inc., Detroit, MI, USA), geriatric depression scale (GDS, 15 items), minimental state examination (MMSE, 30 items), serum biochemical test, serum fasting and 2 hr postprandial homeostasis model assessment (HOMA). Serum insulin levels were determined using a commercially available assay kit (IM-MULITE, I-2000, EURO/Diagnostic Products Cooperation, Gwynedd, UK). The following formula was used to calculate HOMA-IR: HOMA-IR = fasting insulin (μU/mL) × fasting glucose (mmol/L)/22.5 (8, 9) . The plasma PAI-1 level was measured by ELISA (American Diagnostica Inc., Greenwich, CT, USA). The intra-assay and inter-assay CVs of PAI-1 were 3.85% and 4.60%, respectively, with a sensitivity of 1 ng/dL.
The determination of polymorphism of APOE gene involved amplification by PCR using sense primer 5´-TCCAA GGACCTGCAGGCGGCGCA-3´and anti-sense primer 5´-A CAGAATTCGCCCCGGCCTGGTACACTGCCA-3´, and the PCR products were digested with the restriction enzyme HhaI. The polymorphism of Cystatin gene was amplified using sense primer 5´-TGGGAGGGACGAGGCGTTCC-3´and anti-sense primer 5´-TCCATGGGGCCCACCAG-3´, and the PCR products (318 bp) were digested by restriction enzyme The clinical dementia rating (CDR) scale, a structured questionnaire which includes 6 domains memory, orientation, judgment, problem solving, community affairs, home function, and personal care (10) was used by psychiatrists and nurses to interview participants for assessment of cognitive ability at the first and last interview. A score of 0 points in the CDR scale indicated no dementia, 0.5 points was considered to be very mild dementia, and a score of more than 0.5 points was defined as moderate/severe dementia. The patients were grouped based on their CKD status using the lean body mass-adjusted Cockcroft-Gault equation (11) . The CKD patients were assigned to one of two groups: relatively good renal function (eGFR 49 mL/min) or relatively poor renal function (eGFR <49 mL/min). The subjects were further categorized into two subgroups: those who had normal cognition and those who had progression of cognitive dysfunction from CDR 0 to 1 or CDR 1 to 2 at the end of the 3-year follow-up study.
Data analysis
All data analyses were performed using SPSS 12.0. Chisquare analysis was used to compare demographic information between subjects who had normal cognition and those who had cognitive decline by the end of the 3-year follow-up study. Independent paired t test was used for continuous variants. Simple and multivariate logistic regression analyses were used to identify factors that predicted progression of cognitive function in patients with different levels of kidney function. A p value of less than 0.05 was considered as significant.
Results
The mean age of the patients at enrollment was 78.1±3.6 years. Cumulative incidence of cognitive impairment was 17.7% (63/356). At the end of the study period, the 125 residents who remained in the study population included 60 subjects with normal cognition and 65 subjects with cognitive decline. The causes of the mortality were respiratory diseases (n=26), sepsis (n=20), frailty (n=15), heart diseases (n=15), stroke (n=2), liver diseases (n=3), kidney diseases (n=2), cancer (n=8), accident (n=3), and suicide (n=3) (Fig. 1 ). The evolution of cognitive function was further stratified by eGFR with a cut-off point of 49 mL/min ( Fig. 2 ). Demographic characteristics of the elderly patients at the start of the prospective study showed no significant difference between the 231 subjects who were lost to follow-up and the 125 subjects who remained in the study population (Table 1) . Table 2 shows the demographic data of patients with and without progression of cognitive dysfunction based on kidney function. Older age was associated with more deterioration of cognitive function in patients with worse eGFR (p=0.032). Table 2 also shows that patients with progressive cognitive decline in both eGFR subgroups had significantly lower MMSE (p=0.000). There was no significant difference in serum creatinine between these patients with and without progression of cognitive dysfunction (Table 3) . Although HOMA fasting, fasting serum homocysteine, and PAI-1 were significantly different in the relatively low eGFR group (Table 3) , there was no significance after adjusting for multiple confounding factors. In the results of the gene polymorphism analyses (Table 4 ), no significant differences between groups were found. Using mul- tivariate logistic regression models (Table 5) , older age (OR=1.27, 95% CI=1.00-1.61) was found to be associated with a high risk of cognitive decline in patients with relatively poor eGFR. However, a high MMSE score (OR=0.23, 95% CI=0.10-0.54) was correlated with a low risk of progression of cognitive dysfunction in patients with a relatively low eGFR. Those with better eGFR and who had a high MMSE score (OR=0.39, 95% CI=0.23-0.65) were at low risk for developing cognitive dysfunction. MMSE was a negative predictor of cognitive progression in both eGFR groups. Subjects with better eGFR and elevated serum PA1-1 were at high risk for development of cognitive dysfunction (OR=1.06, 95% CI=1.01-1.11). In patients with higher eGFR, TT genotype of TNF-α polymorphism was not associated with cognitive decline or deterioration (OR=0.22, 95% CI=0.05-1.11).
Discussion
Cognitive dysfunction is relatively common in aged people, and the incidence ranges between 15% and 20%. Approximately 12-15% of cases will progress to Alzheimer's disease or other dementia each year (12) . Several factors may contribute to the progression of cognitive function, namely, cardiovascular disease, hypertension, type 2 diabetes mellitus, oxygen deprivation due to chronic obstructive pulmonary disease and obstructive sleep apnea, nutritional deficiency, thyroid dysfunction, medications, depression, and de-lirium (12) . Chronic kidney disease is relatively common in aged people and may be one of the contributing factors in cognitive dysfunction (2) . In those with poor renal function (eGFR <49 mL/min), 32 out of 62 (51.6%) experienced cognitive decline and in those with good renal function (eGFR >49 mL/min), 33 out of 63 (52.4%) experienced cognitive decline. The present study showed that the risk factors of cognitive decline or deterioration were different in patients with different level of kidney function (Table 2-4) , implying a complex interaction of kidney functions and various risk factors. However, there seems to be no difference in incidence of cognitive decline between those with lower eGFR and those with better eGFR. However, the INVADE study proved that moderate-to-severe impaired renal function (eGFR: 30-60 mL/min/1.73 m 2 ) was independently associated with new cognitive impairment after the 2-year followup (13) . We also investigated others factors affecting cognitive decline or deterioration that were not related to renal function.
Although diabetes mellitus is strongly correlated with progression of cognitive function, the role of insulin resistance is less well-defined (14) . We found no correlation of HOMA index and cognitive decline or deterioration after adjustment for various factors. Elevated serum PAI-1 level, an atherothrombotic biomarker, has been shown to be associated with endothelial dysfunction, vascular homeostasis, platelet dysfunction, and thrombogenicity (15) . The Edinburgh Artery Study showed no significant effects of PAI-1 genotypes on the risks of coronary and peripheral atherosclerosis (16) . Moreover, there was no association between cognitive dysfunction and elevated serum PAI-1 in a previous study (15) . In the present study, elevated serum PAI-1 level was correlated with greater cognitive decline or deterioration in patients with good eGFR (Table 3) , and this was confirmed in multivariate logistic regression (Table 5 ). Our findings suggest that serum PAI-1 level may serve as a useful screening tool to identify elder patients at risk for cognitive decline or deterioration. Hyperhomocysteinemia has been proven to be a risk factor for dementia and Alzheimer's disease (17) . Although we found that a higher se-rum level of homocysteine was associated with cognitive decline or deterioration in patients with lower eGFR (Table 3) , the significance was lost after adjusting for age, MMSE, chronic disease numbers, lifestyle, and PAI-1. This result is consistent with the findings of a study by Midorikawa et alon the relationship between homocysteine and the fibrinolytic system which showed that hyperhomocysteinemiainduced atherosclerosis and/or thrombosis may be caused by homocysteine-induced stimulation of PAI-1 gene expression (18) . The Cardiovascular Health Cognition Study showed a high percentage of patients homozygous or heterozygous for (2) . A lack of association between TNF-α-308G/A & C-850T polymorphism and the risk of developing late-onset Alzheimer's disease has been noted in different races and populations (19) . However, some inflammatory markers, such as TNF, are associated with disuse atrophy and very early onset of frailty, while elevated serum IL-6 and CRP indicate a high risk of mortality (20) . We found no correlation of APOE, Cystatin, CRP, and TNF-α polymorphism with cognitive decline or deterioration ( Table 4 ). One of the main purposes of this study was to identify factors that were associated with cognitive decline in patients with chronic kidney disease. We established a model for those with relatively good renal function and another model for those with relatively poor renal function, and then interpreted these models separately. Thus, in patients with poor kidney function, the models showed that age and MMSE were significant factors in the development of cognitive decline, whereas in patients with good kidney function, MMSE and PAI-1 were found to be significant factors in predicting cognitive decline.
The main limitation in our longitudinal study was that of the 356 recruited patients, only 125 were followed up throughout the entire period leaving 65% that dropped out prematurely. The mean life expectancy of Taiwanese males is 75.88 years old. Most of them died or were transferred to another institute with dependent status. A loss of participants of this magnitude may have influenced the validity of the study. However, the baseline characteristics of these 2 groups showed no significant differences which might minimize a selection bias. Because eGFR is a continuous variable, the choice of 49 mL/min as a cut-off point to stratify our patients was arbitrary and might affect the statistical significance. Nevertheless, a similar cut-off point has been used in previous studies (2, 13) . Serum creatinine was highly skewed in our cohort. The older persons should be considered as having renal insufficiency. The mean ± SD value of the eGFR, which was adjusted by lean body mass, was 38.9±10.8 mL/min/1.73 m 2 . Therefore, we used the median of total eGFR values to separate the total patients into two groups. MMSE has been shown to be influenced by different education level, and may not be very accurate in less educated elder patients. In addition, it is difficult to precisely measure cognitive dysfunction, especially in the elderly.
Conclusion
In conclusion, we have demonstrated that older age and a low MMSE score were risk factors of progression of cognitive dysfunction in patients with relatively severe CKD. The risk factors of cognitive decline or deterioration in patients with relatively mild CKD were low MMSE score and high serum PAI-1. MMSE and serum Cr may be useful screening tools for the early identification of patients at high risk for developing cognitive dysfunction.
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